一个功能代谢学框架来跟踪微生物组药物代谢
bioRxiv : the preprint server for biology
|February 12, 2026
概括
这项研究引入了一种新方法来发现肠道微生物产生的药物代谢物. 这些发现揭示了复杂的代谢途径和微生物群落与药物转化之间的联系,改善了对药物的理解.
科学领域:
- 微生物学 微生物学
- 药理学 药理学是指药理学的学科.
- 代谢学 代谢学 代谢学
背景情况:
- 肠道微生物通过转化药品,显著影响药物的疗效和副作用.
- 发现这些微生物组衍生的药物代谢物对于药物开发和个性化医学至关重要.
- 目前在复杂的微生物环境中识别药物代谢物的方法有限.
研究的目的:
- 开发和验证功能性代谢学工作流程,以加速发现微生物组衍生药物代谢物.
- 在合成肠道微生物群体中研究临床药物的化学转化动态.
- 建立微生物群落组成和药物生物转化过程之间的联系.
主要方法:
- 利用合成微生物群落 (SynComs) 来建模肠道微生物药物代谢.
- 采用时间序列解决的分子网络来进行全面的代谢物概况.
- 集成的先进计算工具,用于准确的代谢物注释和分析.
主要成果:
- 确定了大量的药物代谢物,包括复杂的多步代谢级联.
- 观察到特定药物代谢物和SynCom.Com.内的微生物种类的变化之间的相关性.
- 在50种药物小组中展示了框架能够阐明药物转化动态的能力.
结论:
- 开发的功能代谢学工作流程有效地加速了肠道微生物产生的药物代谢物的发现.
- 研究结果表明,肠道微生物组组成和药物生物转化之间存在功能联系,这会影响制药结果.
- 计算分析工作流是公开的,促进了生物转化和化学生态学的更广泛的研究.
相关概念视频
Drug Metabolism: Phase I Reactions
5.1K
A phase I reaction is a biochemical process that introduces a functionally reactive polar group to a substance. This transformation predominantly occurs in the liver, facilitated by the cytochrome P450 system of hemoproteins situated in the lipophilic endoplasmic reticulum of cells. The metabolite generated through this process can have varying polarities. If it is sufficiently polar, it can be easily excreted in the urine due to its water compatibility. However, if the metabolite is nonpolar,...
5.1K
Drug Metabolism: Phase II Reactions
5.2K
Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...
5.2K
Pharmacogenetics of Drug Metabolism: Overview
4
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
4
Pharmacokinetics in Pediatric Patients: Drug Metabolism
246
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
246
What is Metabolism?
132.4K
Overview
132.4K
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
234
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
234


